Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript

Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET

Company Participants

James Carbonara – IR, HaydenIR
Jennifer Simpson – President & CEO
Susan Horvath – CFO

Conference Call Participants

Jonathan Aschoff – Roth Capital Partners

Operator

Good afternoon, everyone, and welcome to the Panbela Therapeutics First Quarter 2024 Earnings Call. [Operator Instructions].

I will now turn the conference over to your host, James Carbonara, Investor Relations. James, over to you.

James Carbonara

Thank you, operator. Joining me on today’s call are Jennifer Simpson, Chief Executive Officer; and Sue Horvath, Chief Financial Officer .

Before we begin, please note that statements made on this call that are not historical facts may be considered forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements are detailed in the company’s filings with the SEC.

Any forward-looking statements made on this call speak only as of today’s date. And the company does not undertake any obligation to update or revise any of these statements to reflect future events or circumstances.

With that, I will turn the call over to Dr. Simpson. Jennifer, please go ahead.

Jennifer Simpson

Thank you, James, and thank you all for joining us. I will start by discussing our clinical development program, recent achievements, and upcoming milestones. Then Sue will review our financial results before we open up the call for Q&A.

Let us begin with our Phase III ASPIRE global clinical trial. ASPIRE is evaluating ivospemin, or SBP-101, in combination with gemcitabine and nab-paclitaxel for patients with untreated metastatic pancreatic ductal adenocarcinoma.

We were excited to announce in January that the ASPIRE enrollment has surpassed 50%, proceeding faster than initially anticipated. With all sites are now open and actively enrolling, we expect full enrollment